SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms SU2C-SARC032
- 16 Mar 2018 Status changed from active, no longer recruiting to recruiting.
- 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2017 Status changed from not yet recruiting to recruiting.